[Properties and features of nabumetone]

Area of Science:

• Pharmacology
• Rheumatology

Background:

• Nabumetone is a nonsteroidal anti-inflammatory drug (NSAID) belonging to the 2,6-disubstituted naphthylalkanone class.
• It functions as a prodrug, metabolized into 6-methoxy-2-naphthylacetic acid (6-MNA), which selectively inhibits cyclo-oxygenase-2 (COX-2).

Purpose of the Study:

• To evaluate the efficacy and tolerability of nabumetone in treating rheumatoid arthritis and osteoarthritis.
• To compare nabumetone's pharmacokinetic and pharmacodynamic properties with other NSAIDs.

Main Methods:

• Nabumetone's metabolism to 6-MNA via first-pass metabolism.
• Analysis of 6-MNA concentrations in plasma and synovial fluid.
• Assessment of gastrointestinal and renal adverse effect profiles.
• In vitro cartilage tolerability studies.

Main Results:

• Nabumetone demonstrates efficacy comparable to other NSAIDs for rheumatoid arthritis and osteoarthritis.
• The active metabolite 6-MNA achieves sustained concentrations in synovial fluid and has a long plasma half-life (20-24 hours), allowing once-daily dosing.
• Nabumetone exhibits a favorable gastrointestinal and renal adverse effect profile compared to other NSAIDs, with good in vitro cartilage tolerability.

Conclusions:

• Nabumetone's unique pharmacokinetic and pharmacodynamic properties, including preferential COX-2 inhibition and a favorable tolerability profile, make it a valuable option for managing chronic arthropathies.
• Further research is needed to determine its clinical utility in cardiovascular disorders.